BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 30968711)

  • 1. Immunomodulatory effects of chemotherapy on blood lymphocytes and survival of patients with advanced non-small cell lung cancer.
    Aldarouish M; Su X; Qiao J; Gao C; Chen Y; Dai A; Zhang T; Shu Y; Wang C
    Int J Immunopathol Pharmacol; 2019; 33():2058738419839592. PubMed ID: 30968711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of Peripheral Effector CD8 T-cell Proliferation by Combination of Paclitaxel, Carboplatin, and Bevacizumab in Non-small Cell Lung Cancer Patients.
    de Goeje PL; Poncin M; Bezemer K; Kaijen-Lambers MEH; Groen HJM; Smit EF; Dingemans AC; Kunert A; Hendriks RW; Aerts JGJV
    Clin Cancer Res; 2019 Apr; 25(7):2219-2227. PubMed ID: 30642911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral PD1-positive CD4 T-Lymphocyte Count Can Predict Progression-free Survival in Patients With Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor.
    Inomata M; Kado T; Okazawa S; Imanishi S; Taka C; Kambara K; Hirai T; Tanaka H; Tokui K; Hayashi K; Miwa T; Hayashi R; Matsui S; Tobe K
    Anticancer Res; 2019 Dec; 39(12):6887-6893. PubMed ID: 31810958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer.
    Ottonello S; Genova C; Cossu I; Fontana V; Rijavec E; Rossi G; Biello F; Dal Bello MG; Tagliamento M; Alama A; Coco S; Boccardo S; Vanni I; Ferlazzo G; Moretta L; Grossi F; Mingari MC; Carrega P; Pietra G
    Front Immunol; 2020; 11():125. PubMed ID: 32117275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study.
    Yan Y; Wang X; Liu C; Jia J
    BMC Pulm Med; 2022 Apr; 22(1):166. PubMed ID: 35484541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors.
    Peng L; Wang Y; Liu F; Qiu X; Zhang X; Fang C; Qian X; Li Y
    Cancer Immunol Immunother; 2020 Sep; 69(9):1813-1822. PubMed ID: 32350592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of Pembrolizumab on T Lymphocyte Subsets in Patients with Advanced 
Non-small Cell Lung Cancer and Its Therapeutic Effect].
    Wang Y; Wang Y; Jiang M; Zhao Y; Zhang X
    Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):182-187. PubMed ID: 33819968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD4
    Kagamu H; Kitano S; Yamaguchi O; Yoshimura K; Horimoto K; Kitazawa M; Fukui K; Shiono A; Mouri A; Nishihara F; Miura Y; Hashimoto K; Murayama Y; Kaira K; Kobayashi K
    Cancer Immunol Res; 2020 Mar; 8(3):334-344. PubMed ID: 31871122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disturbed Th17/Treg Balance in Patients with Non-small Cell Lung Cancer.
    Duan MC; Han W; Jin PW; Wei YP; Wei Q; Zhang LM; Li JC
    Inflammation; 2015 Dec; 38(6):2156-65. PubMed ID: 26077695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamics of peripheral T cell clones during PD-1 blockade in non-small cell lung cancer.
    Zhang F; Bai H; Gao R; Fei K; Duan J; Zhang Z; Wang J; Hu X
    Cancer Immunol Immunother; 2020 Dec; 69(12):2599-2611. PubMed ID: 32591861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC.
    Mazzaschi G; Facchinetti F; Missale G; Canetti D; Madeddu D; Zecca A; Veneziani M; Gelsomino F; Goldoni M; Buti S; Bordi P; Aversa F; Ardizzoni A; Quaini F; Tiseo M
    Lung Cancer; 2019 Jan; 127():153-163. PubMed ID: 30642544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations between peripheral blood lymphocyte subsets and clinical outcomes in patients with lung cancer treated with immune checkpoint inhibitor.
    Li P; Qin P; Fu X; Zhang G; Yan X; Zhang M; Zhang X; Yang J; Wang H; Ma Z
    Ann Palliat Med; 2021 Mar; 10(3):3039-3049. PubMed ID: 33849094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Lymphocyte Subsets on Chemotherapy Efficacy and Long-term Survival of Patients with Advanced Non-small-cell Lung Cancer.
    Wei Z; Zhang W; Gao F; Wu Y; Zhang G; Liu Z; Jiao S
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Jun; 39(3):371-376. PubMed ID: 28695808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer.
    Zheng H; Liu X; Zhang J; Rice SJ; Wagman M; Kong Y; Zhu L; Zhu J; Joshi M; Belani CP
    Oncotarget; 2016 Aug; 7(35):56233-56240. PubMed ID: 27191652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripheral CD4
    Yang X; Li Q; Zeng T
    Front Immunol; 2024; 15():1364507. PubMed ID: 38650951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
    Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
    Iversen TZ
    Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of circulating regulatory T cell subsets in untreated non-small cell lung cancer patients.
    Kotsakis A; Koinis F; Katsarou A; Gioulbasani M; Aggouraki D; Kentepozidis N; Georgoulias V; Vetsika EK
    Sci Rep; 2016 Dec; 6():39247. PubMed ID: 27976733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A trial of autologous ex vivo-expanded NK cell-enriched lymphocytes with docetaxel in patients with advanced non-small cell lung cancer as second- or third-line treatment: phase IIa study.
    Yang YJ; Park JC; Kim HK; Kang JH; Park SY
    Anticancer Res; 2013 May; 33(5):2115-22. PubMed ID: 23645763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
    Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME
    Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.